News | April 14, 2024
Briefs: Sun Pharma and Kimia Biosciences
Sun Pharma's Dadra facility receives OAI status from US FDA
Sun Pharma's Dadra facility receives OAI status from US FDA
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)